1. Home
  2. |Insights
  3. |It's All In The Name

It's All In The Name

Client Alert | less than 1 min read | 10.14.09

In Wackenhut Int'l, Inc. v. Dep't of State (Sept. 22, 2009), the Civilian Board of Contract Appeals ("CBCA") ;dismissed for lack of jurisdiction when the appellant's Contract Disputes Act claim and subsequent appeal to the CBCA were brought in the name of a single joint venture partner instead of the joint venture itself. The Board found that only the joint venture had privity of contract with the government and that that was altered neither by appellant's 51% ownership stake in the joint venture nor by appellant's obtaining written authorization to pursue the claim from its joint venture partner.

Insights

Client Alert | 3 min read | 11.17.26

CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs

On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.  ...